Basic Calan Sr Information

• INN (International Nonproprietary Name): Verapamil
• Brand Names Available In Australia: Calan, Calan SR; Isoptin, Isoptin SR; Verelan, Verelan PM; Covera‑HS; Tarka; Vérapamil / Verapamilo / Verapamilum (brand availability by region varies; check ARTG/TGA for local listings)
• ATC Code: C08DA01
• Forms & Dosages: Immediate‑release tablets 40 mg, 80 mg, 120 mg; Extended‑release tablets/capsules 120 mg, 180 mg, 240 mg
• Manufacturers In Australia: Pfizer (Calan SR—international brand), Abbott Laboratories, Knoll, Mylan, Sandoz and numerous generics (local supply varies; check ARTG/TGA listings)
• Registration Status In Australia: not specified
• OTC / Rx Classification: Prescription‑only (Rx) medicine in major markets; always confirm current local classification

Latest Research Highlights

Clinicians frequently ask whether verapamil SR still has a clear role in modern practice.

Recent Australian and international reviews from 2022–2025 have reinforced verapamil’s established role for rate control in supraventricular tachycardia and for chronic stable angina in patients who cannot tolerate beta‑blockers or dihydropyridine calcium channel blockers.

Registry analyses and TGA‑linked pharmacovigilance summaries mirror global data showing effective rate control but a higher rate of bradycardia and conduction disturbances compared with dihydropyridine CCBs.

Randomised trials and pooled meta‑analyses during 2022–25 emphasise the need for careful risk stratification before selecting verapamil, especially where beta‑blockers are co‑prescribed.

Pharmacokinetic work highlights the advantages of extended‑release formulations (SR/ER) such as smoother plasma levels, fewer peak‑related adverse events and improved adherence versus immediate‑release dosing.

Drug interaction signal analyses in recent safety pools call attention to CYP3A4 substrate and inhibitor effects; macrolide antibiotics and some azole antifungals are notable interaction concerns.

For Australian practice, telehealth prescribing studies show once‑daily SR formulations suit e‑scripts and rural dispensing workflows.

Study Snapshot

Clinical Effectiveness In Australia

Patients often want to know whether verapamil works as well here as in trials overseas.

In Australia verapamil (INN: verapamil; ATC C08DA01) produces consistent reductions in blood pressure and angina symptoms when used per guideline recommendations.

Extended‑release products make once‑daily dosing practical and increase adherence in long‑term therapy compared with immediate‑release three‑times‑daily regimens.

TGA adverse‑event summaries and PBS prescribing data (where applicable) show expected benefits balanced against common adverse effects such as constipation, peripheral oedema and bradycardia.

Primary care and cardiology clinics typically select verapamil SR for patients who experience amlodipine‑related flushing or where beta‑blockers are contraindicated.

Australian tertiary arrhythmia services continue to use intravenous and oral verapamil for acute SVT conversion, with oral SR formulations for maintenance in selected patients under specialist review.

Practical effectiveness is enhanced by pharmacist counselling on dose timing and on the instruction to never crush sustained‑release tablets.

Typical Responses By Indication

• SVT Rate Control: Rapid rate reduction and symptom relief with IV/oral therapy in selected cases.
• Chronic Stable Angina: Symptom reduction comparable to other non‑dihydropyridine agents when tolerated.
• Hypertension: Useful in patients with comorbid coronary disease or contraindication to first‑line agents; SR dosing simplifies adherence.

Indications And Expanded Uses

People ask what verapamil is officially used for and when specialists might prescribe it off‑label.

TGA‑aligned and widely accepted indications include hypertension, chronic stable angina and certain supraventricular arrhythmias such as SVT.

Standard adult dosing ranges from immediate‑release 80–120 mg three times daily for angina to extended‑release 180–240 mg once daily for hypertension, with arrhythmia regimens often totalling 240–320 mg/day divided.

Off‑label specialist uses in Australia, under cardiology oversight, include rate control for selected atrial flutter or atrial fibrillation patients and tailored symptom relief in hypertensive patients with coronary disease where other agents are unsuitable.

Paediatric use is rare and always weight‑based under specialist supervision.

Absolute contraindications such as advanced heart block, severe hypotension and severe heart failure mean verapamil is unsuitable for some patients.

TGA‑Approved Uses Vs Common Off‑Label Uses

• Approved: Hypertension, chronic stable angina, selected supraventricular arrhythmias.
• Common Off‑Label (Specialist Use): Rate control in atrial flutter/fibrillation for selected patients; specialist‑directed paediatric arrhythmia management.

Composition And Brand Landscape

Patients commonly ask which brands and strengths are available and whether branded SR tablets differ from generics.

The active ingredient is verapamil, most often supplied as verapamil hydrochloride in various formulations.

Global brand names include Calan/Calan SR, Isoptin/Isoptin SR, Verelan, Covera‑HS and multiple generics supplied by manufacturers such as Pfizer, Abbott, Mylan and Sandoz.

Internationally relevant dosage forms are immediate‑release tablets 40/80/120 mg and extended‑release tablets/capsules 120/180/240 mg.

In Australia, generic verapamil products and branded imports appear from time to time; pharmacists should check the ARTG/TGA and PBS for the latest local listings and subsidy status.

For price‑sensitive patients, major pharmacy chains and accredited online pharmacies stock generics and occasionally branded imports.

Brands, Manufacturer And Dose Forms

Contraindications And Special Precautions

Patients often worry whether verapamil is safe for them given other health problems.

Absolute contraindications include severe hypotension (systolic <90 mmHg), second‑ or third‑degree AV block without a pacemaker, sick sinus syndrome without pacemaker, known hypersensitivity and severe heart failure.

Special population cautions: start lower in elderly patients and monitor closely for hypotension and bradycardia.

People in remote or Indigenous communities may have higher comorbidity burdens such as diabetes and chronic kidney disease that require dose adjustment and culturally safe counselling.

Pregnancy and breastfeeding are generally considered situations for specialist oversight and avoidance unless benefits clearly outweigh risks.

Combination with beta‑blockers raises the risk of heart block and requires ECG and rate monitoring.

Monitoring Checklist

• Baseline blood pressure and pulse before starting.
• ECG if symptomatic, or before combining with other negative chronotropes.
• Review at 1–2 weeks for heart‑rate and blood‑pressure response, then at 3 months for efficacy and tolerability.
• Check liver function in suspected hepatic impairment and adjust dose if required.
• Urgent review for syncope, severe dizziness, sudden breathlessness or marked bradycardia.

Dosage Guidelines

Many patients ask: how should I take verapamil SR versus IR, and what happens if I miss a dose?

Typical adult dosing mirrors standard product information: immediate‑release 80–120 mg three times daily for angina, and extended‑release 120–240 mg once daily for hypertension, with arrhythmia maintenance commonly totalling 240–320 mg/day divided.

Start lower in elderly patients and those with hepatic impairment, and titrate to clinical effect while monitoring blood pressure and heart rate.

For rural patients using telehealth, once‑daily SR formulations simplify prescribing and dispensing; pharmacists should advise patients never to crush or chew SR/ER tablets.

Renal impairment usually requires less adjustment than hepatic impairment, but monitor for increased plasma levels and bradycardia.

If a dose is missed, take as soon as remembered unless close to the next dose; do not double doses.

Overdose is a medical emergency; present to hospital for severe hypotension or bradycardia where IV calcium, vasopressors or pacing may be needed.

Practical Dosing Table

Interactions Overview

One frequent question is whether verapamil mixes safely with other medicines or common foods.

Verapamil is a CYP3A4 interactor and a P‑glycoprotein substrate, so expect clinically relevant interactions with CYP3A4 inhibitors and inducers.

Combining verapamil with other negative chronotropes such as beta‑blockers or digoxin increases the risk of bradycardia and AV block; ECG and pulse monitoring are advised.

Grapefruit juice can raise verapamil levels and should be avoided on a regular basis.

Some macrolide antibiotics and azole antifungals can increase verapamil exposure; dose review or alternative therapy should be considered.

St John’s wort (a CYP inducer) may lower verapamil levels and reduce effectiveness.

Interaction Matrix

Cultural Perceptions And Patient Habits

Many Australian patients care about cost, brand and how a medicine will affect their day‑to‑day life.

Price sensitivity leads many to favour PBS‑subsidised generics or discount chains such as Chemist Warehouse when available.

Community pharmacists are trusted and commonly provide practical counselling on sustained‑release use and side‑effects like constipation and fatigue.

Rural and remote patients often receive e‑scripts via telehealth and pick up medicines locally, but stock limitations for a specific SR brand can affect continuity.

Indigenous patients may prefer face‑to‑face, culturally safe consultations and may need extra support coordinating local monitoring and follow‑up.

Online forums frequently discuss side‑effects, and proactive pharmacist counselling reduces unnecessary discontinuation.

Barriers And Counselling Tips

• Barrier: Stock shortages of a preferred SR brand; Tip: explain therapeutic substitution and document prescriber preferences.
• Barrier: Cost pressure; Tip: ask about concession cards and PBS eligibility at dispensing.
• Barrier: Cultural or language differences; Tip: use culturally safe communication and involve local health services.

Availability And Pricing Patterns

Patients want to know where to buy calan sr and how much it will cost.

Major pharmacy chains and accredited online pharmacies commonly stock generic verapamil and occasionally branded imports; exact availability depends on ARTG/TGA and PBS listings.

If a product is not PBS‑listed, expect private pricing that varies by brand and supplier.

Pharmacists may supply therapeutically equivalent generics with prescriber consent during shortages to avoid treatment interruption.

For cost transparency, advise patients to ask their pharmacy about PBS eligibility, concession pricing and generic substitution options.

In our online pharmacy, calan sr is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Where To Check Supply And Price

• Check TGA ARTG listings for registered products and sponsor details.
• Ask your pharmacist about PBS listings and concession pricing.

Comparable Medicines And Preferences

People often ask whether verapamil is better than other calcium channel blockers or beta‑blockers.

Alternatives include diltiazem (Cardizem/Tiazac), dihydropyridine CCBs such as amlodipine (Norvasc), and beta‑blockers like atenolol or metoprolol depending on the indication.

Verapamil’s strengths are effective rate control and anti‑anginal efficacy without the vasodilatory flushing seen with dihydropyridines.

Its downsides are a higher incidence of constipation and AV‑conduction risks versus amlodipine, and it is not usually first‑line for isolated hypertension without angina.

Choose verapamil when beta‑blockers are contraindicated, when arrhythmia rate control is required, or when a non‑dihydropyridine CCB is preferred.

Decision Matrix

Frequently Asked Questions

Patients ask short practical questions about use, monitoring and safety.

Q: Can I crush Calan SR or other verapamil SR tablets?

A: No. Do not crush or chew extended‑release tablets as this alters the release profile and increases the risk of side effects.

Q: Is verapamil on the PBS?

A: Availability and subsidy vary by product and indication; check current PBS and ARTG/TGA listings or ask your pharmacist for up‑to‑date advice.

Q: What should I monitor while taking verapamil?

A: Regular blood pressure and pulse checks, and an ECG if symptoms arise or when combining with beta‑blockers; check liver function in hepatic impairment.

Q: Can I drink grapefruit juice?

A: Avoid regular grapefruit juice as it increases verapamil blood levels and the risk of side effects.

Emergency Signs: Seek urgent care for fainting, severe dizziness, chest pain, sudden breathlessness or very slow pulse.

Guidelines For Proper Use

When patients ask what the pharmacist will tell them, a clear counselling script helps.

Key counselling points: take sustained‑release tablet whole at the same time each day; do not crush or chew; expect common effects such as constipation, dizziness or ankle swelling; avoid regular grapefruit juice.

Advise patients to report fainting, light‑headedness, very slow pulse or worsening breathlessness immediately.

Document indication on the e‑script for PBS checks and note any brand preference to support continuity of supply.

For rural or telehealth patients, coordinate with a local pharmacy to ensure timely dispensing and arrange local BP and ECG monitoring if required.

Clinicians should consider a baseline ECG and periodic review when combining verapamil with beta‑blockers or digoxin, and reduce dose in hepatic impairment.

Pharmacist Counselling Checklist

• Explain indication and dosing schedule; demonstrate taking SR tablet whole.
• Review common side effects and when to seek urgent care.
• Check other medicines and counsel on interactions (grapefruit, macrolides, antifungals).
• Arrange monitoring timeline: baseline, 1–2 weeks, 3 months.

Delivery Across Australia